KDR and sarcoma: Sarcomas, as with many other tumors, require the recruitment of circulating endothelial progenitor cells to initiate and sustain new blood vessels from preexisting vessels[5], making the vascular endothelial growth factor receptor (VEGFR) a key target for therapy.